Seasonal Influenza Vaccine

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Seasonal Influenza

Conditions

Seasonal Influenza

Trial Timeline

May 1, 2011 → Jun 1, 2011

NCT ID

NCT01344057

About Seasonal Influenza Vaccine

Seasonal Influenza Vaccine is a phase 2 stage product being developed by Novartis for Seasonal Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT01344057. Target conditions include Seasonal Influenza.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01422512	Phase 3	Completed	Sep 1, 2011	Oct 1, 2011	Influenza
NCT01344057	Phase 2	Completed	May 1, 2011	Jun 1, 2011	Seasonal Influenza
NCT01357265	Phase 2	Completed	May 1, 2011	Jun 1, 2011	Influenza
NCT00956449	Phase 2	Completed	Jun 1, 2009	Jul 1, 2009	Influenza
NCT00735410	Phase 3	Completed	Jun 1, 2008	Jul 1, 2008	Seasonal Influenza, Vaccine
NCT00734734	Phase 2	Completed	Jun 1, 2008	Jul 1, 2008	Interpandemic Influenza

Competing Products

20 competing products in Seasonal Influenza

See all competitors

Product	Company	Stage	Hype Score
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	77
ASP4070 + Placebo	Astellas Pharma	Phase 2	52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)	Glenmark Pharmaceuticals	Phase 2	52
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray	Glenmark Pharmaceuticals	Phase 2	52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placebo	Johnson & Johnson	Phase 1	33
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + Placebo	AstraZeneca	Phase 2	52
budesonide + Placebo	AstraZeneca	Phase 2	52
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide Nasal Spray	AstraZeneca	Phase 3	77
Budesonide + Fluticasone propionate + Placebo	AstraZeneca	Phase 3	77
Ciclesonide + Ciclesonide Placebo	AstraZeneca	Phase 3	77
loratadine	Merck	Pre-clinical	23
MK0524	Merck	Phase 2	52

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved